Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARα agonists on urine pH

Hormone and Metabolic Research

Volumn 39, Issue 7, 2007, Pages 511-514

  Takahashi, S ^a   Inokuchi, T ^a   Kobayashi, T ^a   Ka, T ^a   Tsutsumi, Z ^a   Moriwaki, Y ^a   Yamamoto, T ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Acidic urine; Bezafibrate; Fenofibrate; HOMA R; Hyperuricemia; Insulin

Indexed keywords

ALLOPURINOL; BENZBROMARONE; BEZAFIBRATE; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; GOUT; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE REGRESSION; PRIORITY JOURNAL; RISK FACTOR; URINE PH;

ANTILIPEMIC AGENTS; BEZAFIBRATE; BIOLOGICAL MARKERS; BODY MASS INDEX; GOUT; HUMANS; HYDROGEN-ION CONCENTRATION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEPHROLITHIASIS; PPAR ALPHA; PROCETOFEN; REGRESSION ANALYSIS; TRIGLYCERIDES; URIC ACID;

EID: 34547645460     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-982517     Document Type: Article

References (18)

1. Scott E. Epidemiology of stone disease. Br J Urol 1985; 57: 491-497
2. Yu TF, Gutman AB. Uric acid nephrolithiasis in gout. Ann Intern Med 1967; 67: 1133-1148
3. Pak Poy RK. Urinary pH in gout. Australas Ann Med 1965; 14: 35-39
4. Alvarez-Nemegyei J, Medina-Escobedo M, Villanueva-Jorge S, Vazquez-Mellado J. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? J Rheumatol 2005; 32: 2189-2191
5. Abate N, Chandalia M, Cabo-Chan Jr AV, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestations of insulin resistance. Kidney Int 2004; 65: 386-392
6. Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z. Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther 2004; 42: 212-217
7. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000; 275: 16638-16642
8. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 2002; 296: 293-299
9. Wallace SL, Robinson H, Masi AT, Decker JL, MacCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
11. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62: 572-575
12. Gutman AB, Yu TF. Urinary ammonium excretion in primary gout. J Clin Invest 1965; 44: 1474-1481
13. Falls Jr WF. Comparison of urinary acidification and ammonium excretion in normal and gouty subjects. Metabolism 1972; 21: 433-445
14. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout - influence of alcohol intake and body weight. Br J Rheumatol 1994; 33: 731-734
15. + exchanger 3 (NHE3): biphasic response and glucocorticoid dependence. Am J Physiol Renal Physiol 2002; 283: F532-F539
16. Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988; 66: 140-146
17. Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner AH, Kann P, Forst T. Pioneer study: PPARγ activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res 2005; 37: 510-515
18. Forst T, Hohberg C, Fuellert SD, Lübben G, Konrad T, Löbig M, Weber MM, Sachara C, Gottschall V, Pfützner A. Pharmacological PPARγ stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res 2005; 37: 521-527